Issues in the pharmacological treatment of anxiety disorders

Australasian Psychiatry

Volumn 13, Issue 4, 2005, Pages 371-374

  Starcevic, Vladan ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

Author keywords

Anxiety disorders; Dependence; Efficacy; Pharmacotherapy; Relapse

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; CLONAZEPAM; ESCITALOPRAM; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PREGABALIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; VENLAFAXINE; VIGABATRIN; ANXIOLYTIC AGENT;

ADJUVANT THERAPY; AGITATION; ANXIETY DISORDER; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE EXACERBATION; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LONG TERM CARE; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOTHERAPY; RECURRENCE RISK; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; THERAPY RESISTANCE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; WEIGHT GAIN; ARTICLE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PSYCHIATRY; RECURRENT DISEASE;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; PSYCHIATRY; RECURRENCE;

EID: 33645748336     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2005.02225.x     Document Type: Review

References (34)

1. Shapira NA, Ward HE, Mandoki M et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry 2004; 55: 553-555.
2. Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. Journal of Clinical Psychiatry 2004; 65: 565-568.
3. McDougle CJ, Epperson CN, Pelton GH et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry 2000; 57: 794-801.
4. Hollander E, Rossi NB, Sood E et al. Risperidone augmentation in SRI-resistant obsessive compulsive disorder: A preliminary double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology 2003; 6: 397-401.
5. Woods SW, Nagy LM, Kolesar AS et al. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. Journal of Clinical Psychopharmacology 1992; 12: 32-38.
6. Goddard AW, Brouette T, Almai A et al. Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 2001; 58: 681-686.
7. Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. Journal of Psychopharmacology 2003; 17: 276-282.
8. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 2004; 65: 244-248.
9. Carli V, Sarchiapone M, Camardese G et al. Mirtazapine in the treatment of panic disorder. Archives of General Psychiatry 2002; 59: 661-662.
10. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalizedanxiety disorder. Journal of Clinical Psychopharmacology 2003; 23: 240-249.
11. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. American Journal of Psychiatry 2003; 160: 533-540.
12. Pande AC, Feltner DE, Jefferson JW et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. Journal of Clinical Psychopharmacology 2004; 24: 141-149.
13. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 2005; 62: 190-198.
14. Otto MW, Tuby KS, Gould RA et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 2001; 158: 1989-1992.
15. Schweizer E, Rickels K, Weiss S et al. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry 1993; 50: 51-60.
16. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry 1997; 58: 555-561.
17. Bruce SE, Vasile RG, Goisman RM et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? American Journal of Psychiatry 2003; 160: 1432-1438.
18. Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder: An acute, double-blind noninferiority comparison. Journal of Clinical Psychiatry 2004; 65: 405-413.
19. Ball SG, Kuhn A, Wall D et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: A double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry 2005; 66: 94-99.
20. Sheehan DV, Burnham DB, Iyengar MK et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Journal of Clinical Psychiatry 2005; 66: 34-40.
21. Lepola U, Bergtholdt B, Lambert JS et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 2004; 65: 222-229.
22. Davidson J, Yaryura-Tobias J, DuPont R et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004; 24: 118-125.
23. Westenberg HGM, Stein DJ, Yang H et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004; 24: 49-55.
24. Worthington JW, Pollack MH, Otto MW et al. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacology Bulletin 1998; 34: 199-205.
25. Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. European Psychiatry 2003; 18: 401-408.
26. Stein DJ, Versiani M, Hair T et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Archives of General Psychiatry 2002; 59: 1111-1118.
27. Stocchi F, Nordera G, Jokinen RH et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry 2003; 64: 250-258.
28. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. Journal of Clinical Psychiatry 2004; 65: 1696-1707.
29. Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology 2002; 22: 294-299.
30. Barlow DH, Gorman JM, Shear MK et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529-2536.
31. Starcevic V, Linden M, Uhlenhuth EH et al. Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: Factors influencing psychiatrists' treatment choices. Psychiatry Research 2004; 125: 41-52.
32. Biondi M, Picardi A. Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioural therapy: A follow-up study. Psychotherapy and Psychosomatics 2003; 72: 34-42.
33. Simpson HB, Liebowitz MR, Foa EB et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depression and Anxiety 2004; 19: 225-233.
34. Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. New York: Oxford University Press, 2005.